TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25047139

Group type: EXPERIMENTAL
Intervention: Navitoclax 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Navitoclax 250 mg with Rifampin 600 mg QD
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Navitoclax with Rifampin
Number of subjects: 12
Study: 22951358

Group type: EXPERIMENTAL
Intervention: Iloprost infusion in combination with low dose eptifibatide infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion + eptifibatide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 17
Study: 19944608

Group type: EXPERIMENTAL
Intervention: Augmented low-Dye (ALD) taping
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-tape control
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between ALD taping and control
Number of subjects: 28
Study: 18292851

Group type: EXPERIMENTAL
Intervention: Short individualized educational intervention program based on Prochaska's transtheoretical model for six months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard educational intervention
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Short individualized educational intervention program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Short individualized educational intervention program and standard educational intervention
Number of subjects: 38
Study: 15657372

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 40
Study: 12635062

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg/kg/min
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg/kg/min
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 microg/kg/min
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Remifentanil (all doses)
Number of subjects: 141
Study: 10981888

Group type: EXPERIMENTAL
Intervention: Test-and-eradicate
Number of subjects: 500

Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 500
Study: 8825533

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg tablets on the night before and the morning of surgery, plus isotonic saline 0.3 ml iv before surgery ended.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Droperidol 0.75 mg iv injected before the operation ended.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 60
Study: 1408861

Group type: EXPERIMENTAL
Intervention: Special health care program (experimental group)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Routine well-baby care (control group)
Number of subjects: 243
Study: 3936140

Group type: EXPERIMENTAL
Intervention: Almitrine (200 mg/day for 9 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30854590

Group type: EXPERIMENTAL
Intervention: Circular YAG laser anterior capsulotomy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radial YAG laser anterior capsulotomy
Number of subjects: 66
Study: 29258868

Group type: EXPERIMENTAL
Intervention: Snack meal followed by exercise session (SE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Snack meal only (SO)
Number of subjects: 21
Study: 25348726

Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no HOT)
Number of subjects: 97
Study: 24884672

Group type: EXPERIMENTAL
Intervention: Cervical aiming task in patients with tension-type headache
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical aiming task in healthy participants
Number of subjects: 0
Study: 22044116

Group type: EXPERIMENTAL
Intervention: Conventional braces
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nickel-free braces
Number of subjects: 42
Study: 20969809

Group type: EXPERIMENTAL
Intervention: Patient education programme for osteoarthritis
Number of subjects: 0
Study: 18218179

Group type: EXPERIMENTAL
Intervention: Exenatide (5 mcg twice daily for 4 weeks, then 10 mcg thereafter)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Insulin analogue therapy (glargine or biphasic insulin aspart)
Number of subjects: 1047
Study: 15721095

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5710

Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibition
Number of subjects: 5710

Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 5710
Study: 12678187

Group type: EXPERIMENTAL
Intervention: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10789879

Group type: EXPERIMENTAL
Intervention: 25 mg smoked cocaine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CS+ (conditioned stimulus paired with cocaine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CS+ alone during extinction trials
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo smoked cocaine (CS‐)
Number of subjects: 8
Study: 8640708

Group type: EXPERIMENTAL
Intervention: 25 to 34 mCi of 131 I (30 +/- 1.5)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 35 to 64 mCi of 131 I (50.6 +/- 5.4)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 65 to 119 mCi of 131 I (88.6 +/- 14)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 120 to 200 mCi of 131 I (155 +/- 28.7)
Number of subjects: 149
Study: 1495889

Group type: EXPERIMENTAL
Intervention: 40 mg adinazolam mesylate immediate-release (CT) tablets
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release (SR) tablets
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 40 mg CT tablets every 8 hr
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 60 mg SR tablets every 12 hr
Number of subjects: 31
Study: 3831144

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30661944

Group type: EXPERIMENTAL
Intervention: TiO2 abutment surface
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard abutment surface
Number of subjects: 15
Study: 30105400

Group type: EXPERIMENTAL
Intervention: Daily teriparatide injection (20-μg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Weekly teriparatide injection (56.5-μg)
Number of subjects: 43
Study: 27144848

Group type: EXPERIMENTAL
Intervention: Single dose of oral cholera vaccine Shanchol
Number of subjects: 204700

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 204700
Study: 25151225

Group type: EXPERIMENTAL
Intervention: Aerosol MVA85A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous MVA85A
Number of subjects: 24
Study: 22336292

Group type: EXPERIMENTAL
Intervention: Water-based exercise intervention (n = 60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Land-based exercise intervention (n = 60)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group, n = 60)
Number of subjects: 180
Study: 20131030

Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Decoction (YQYYD) with conventional therapy of Western medicine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional therapy of Western medicine
Number of subjects: 108
Study: 17542349

Group type: EXPERIMENTAL
Intervention: Sarizotan 5-25 mg single doses
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sarizotan 10 and 20 mg b.i.d. multiple doses
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sarizotan 5 mg b.i.d. multiple doses
Number of subjects: 83
Study: 19385450

Group type: EXPERIMENTAL
Intervention: Cervico-thoracic sympathectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 48
Study: 15007784

Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/d, with initial run-in of 150 mg/d for the first three days)
Number of subjects: 321
Study: 11727145

Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 8976225

Group type: EXPERIMENTAL
Intervention: Filiform dilation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Optical internal urethrotomy
Number of subjects: 210
Study: 8387697

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy with fast neutrons (average dose 569 cGy) and photons (average dose 36.86 Gy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Boost therapy or mixed beam therapy with localized fast neutron field
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 39
Study: 3308650

Group type: EXPERIMENTAL
Intervention: TDB 120 mg quid
Number of subjects: 52

Group type: COMPARATOR
Intervention: cimetidine 400 mg tid
Number of subjects: 52

Group type: COMPARATOR
Intervention: cimetidine 400 mg with meals plus 800 mg at bedtime
Number of subjects: 52
Study: 30612569

Group type: EXPERIMENTAL
Intervention: BiodentineTM pulpotomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: formocresol pulpotomy
Number of subjects: 37
Study: 29061008

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral axillary brachial plexus block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neurostimulator-guided bilateral axillary brachial plexus block
Number of subjects: 120
Study: 25776457

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12444

Group type: COMPARATOR
Intervention: GP IIb/IIIa receptor inhibitors
Number of subjects: 12444
Study: 25498776

Group type: EXPERIMENTAL
Intervention: Behavioral economics intervention strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard economic choice theory
Number of subjects: 0
Study: 23264241

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multiple regression model
Number of subjects: 85
Study: 19827696

Group type: EXPERIMENTAL
Intervention: Maladaptive coping strategies
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mental disengagement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Behavioral disengagement
Number of subjects: 51
Study: 18159027

Group type: EXPERIMENTAL
Intervention: Analgecine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Indomethacin tablet
Number of subjects: 44
Study: 16335913

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg) and dienogest (2 mg)
Number of subjects: 34
Study: 11923458

Group type: EXPERIMENTAL
Intervention: Semantically inappropriate sentence-ending words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N100m response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory N400m response
Number of subjects: 0
Study: 9797910

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (1 g calcium carbonate and 14 micrograms vitamin D3)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 240
Study: 8586825

Group type: EXPERIMENTAL
Intervention: Diuretics (altizide and spironolactone)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Beta-blocker (bisoprolol)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (verapamil)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 653
Study: 2473400

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis and food hypersensitivity
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dietary elimination of offending food allergens
Number of subjects: 63

Group type: COMPARATOR
Intervention: Atopic dermatitis without food hypersensitivity
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 63
Study: 1116382

Group type: EXPERIMENTAL
Intervention: Rimiterol (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg)
Number of subjects: 0
Study: 31373886

Group type: EXPERIMENTAL
Intervention: Fluorescence-aided identification technique (FIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional technique (contra-angle handpiece)
Number of subjects: 64
Study: 30552786

Group type: EXPERIMENTAL
Intervention: School-based intervention based on the theory of planned behaviour (TPB)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 382
Study: 29262813

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg (ARB)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ARB + Hydrochlorothiazide 25 mg (HCT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ACE inhibition (Lisinopril 40 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dual RAASi (Lisinopril 40 mg/day + Valsartan 320 mg/day)
Number of subjects: 33
Study: 24795092

Group type: EXPERIMENTAL
Intervention: Intravenous doripenem (DRPM) 0.5 g three times daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) 0.5 g three times daily
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intravenous doripenem (DRPM)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS)
Number of subjects: 127
Study: 23636255

Group type: EXPERIMENTAL
Intervention: Intensive exercise (treadmill training sessions three times/week for 8 weeks)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intensive exercise (treadmill training)
Number of subjects: 4
Study: 22262708

Group type: EXPERIMENTAL
Intervention: 30 min of exercise on a stationary cycle at moderate to vigorous intensity
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group reading for the same length of time
Number of subjects: 42
Study: 19615907

Group type: EXPERIMENTAL
Intervention: Returning gastric residual volume (GRV)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Discarding gastric residual volume (GRV)
Number of subjects: 125
Study: 16924014

Group type: EXPERIMENTAL
Intervention: Central auditory tests (including pure-tone audiometry, tympanometry, dichotic digits, duration pattern, frequency pattern, gaps in noise tests)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gaps in noise test
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cognitive impairment assessment
Number of subjects: 8
Study: 15008344

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 106
Study: 11535336

Group type: EXPERIMENTAL
Intervention: 0, 6 month vaccination schedule
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 0, 12 month vaccination schedule
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined response (both schedules)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 240
Study: 10771863

Group type: COMPARATOR
Intervention: Brainstem auditory evoked response (BAER) abnormalities in tuberculous meningitis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of prolonged latency and prolonged interval
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unilateral and bilateral absent response
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prolonged latency
Number of subjects: 50

Group type: COMPARATOR
Intervention: Seizure activities, modified Glasgow coma scale (GCS), raised intracranial pressure (ICP), and TBM stage III
Number of subjects: 50

Group type: COMPARATOR
Intervention: Age, sex, duration of illness, depressed sensorium, neurological deficit, and CSF findings
Number of subjects: 50

Group type: COMPARATOR
Intervention: Follow up BAER
Number of subjects: 50

Group type: COMPARATOR
Intervention: Initial and follow up BAER
Number of subjects: 50
Study: 8183472

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3328685

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 40
Study: 30958322

Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 10
Study: 28571996

Group type: EXPERIMENTAL
Intervention: Etanercept (TNF-alpha inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study: 27318340

Group type: EXPERIMENTAL
Intervention: Hypothermia continuous blood purification (HT group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Normothermic continuous blood purification (NT group)
Number of subjects: 95
Study: 22383331

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 0
Study: 22064591

Group type: EXPERIMENTAL
Intervention: Irbesartan in HFPEF trial (I‐PRESERVE)
Number of subjects: 4128
Study: 18636266

Group type: EXPERIMENTAL
Intervention: Densiron-68 heavy silicone oil
Number of subjects: 79
Study: 16959828

Group type: EXPERIMENTAL
Intervention: Baseline proteinuria
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: GFR <40 ml/min
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Serum creatinine, urea nitrogen, phosphorus
Number of subjects: 1094
Study: 15488354

Group type: EXPERIMENTAL
Intervention: 1 mg micronised 17 beta‐oestradiol/5 mg dydrogesterone (E/D)
Number of subjects: 362

Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine oestrogens/5 mg medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 362
Study: 11514040

Group type: EXPERIMENTAL
Intervention: New uniform power method for sample size calculation in historical control studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized design formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Makuch and Simon's method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control design
Number of subjects: 0
Study: 9718870

Group type: EXPERIMENTAL
Intervention: ABVD/OPP
Number of subjects: 218

Group type: COMPARATOR
Intervention: ABVD/MOPP
Number of subjects: 218
Study: 7826792

Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, self-administered using PCA, mean 275 micrograms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, administered by a nurse on request, mean 144 micrograms)
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.m. morphine (mean 52 mg, range 30‐80 mg, administered on request)
Number of subjects: 30
Study: 3041935

Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO) for one hour during early reperfusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PICSO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO)
Number of subjects: 30
Study: 31130722

Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) assay (EndoPredict®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 58-gene RS assay (Prosigna®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 21-gene RS assay (Oncotype DX®)
Number of subjects: 0
Study: 31219715

Group type: EXPERIMENTAL
Intervention: Intervention group (strengths-focused HIV prevention program)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Control group (attention control program)
Number of subjects: 860
Study: 28754119

Group type: EXPERIMENTAL
Intervention: YY-312 (2400 mg daily, containing 1800 mg of active herbal extract and 600 mg of cyclodextrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26618455

Group type: EXPERIMENTAL
Intervention: VYC‐20L (hyaluronic acid gel)
Number of subjects: 167
Study: 23110613

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 144
Study: 20863604

Group type: EXPERIMENTAL
Intervention: Natural childbirth preparation with psychoprophylaxis
Number of subjects: 2151

Group type: COMPARATOR
Intervention: Standard antenatal education
Number of subjects: 2151
Study: 19485825

Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg with caffeine 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 15
Study: 17243592

Group type: EXPERIMENTAL
Intervention: ViscoStat (VS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ViscoStat Plus (VS+)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ViscoStat and blood (VS/B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ViscoStat Plus and blood (VS+/B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study: 14686080

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment package targeting headache symptoms and associated posttraumatic stress symptoms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait-list group (Control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment package
Number of subjects: 14
Study: 12549975

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (2 g)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (4 g/day for 4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11024416

Group type: EXPERIMENTAL
Intervention: Topical beta-blockers
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Close observation (no topical medication)
Number of subjects: 1636
Study: 8851288

Group type: EXPERIMENTAL
Intervention: Early intervention (EI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 1729317

Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC) or Streptokinase
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Grade 3 perfusion
Number of subjects: 359
Study: 6362832

Group type: EXPERIMENTAL
Intervention: Immunotherapy with nonviable Mycobacterium smegmatis, given monthly by subcutaneous injection in four sites.
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (not specified treatment).
Number of subjects: 219